Clinical trials: Helicobacter
Autoimmune Diseases, Helicobacter Pylori Gastritis
Pyloric or Pseudopyloric Metaplasia of the Corpus Mucosa in Autoimmune Gastritis
The study is aimed to investigate the different rates of pyloric/ pseudopyloric metaplasia or spasmolytic polypeptide-expressing metaplasia (SPEM) of corpus between autoimmune gastritis and H. pylori-infected non-ulcer dyspepsia.
- Conditions
- Autoimmune Diseases, Helicobacter Pylori Gastritis, Anemia, Pernicious, Metaplasia
- Trial name
- PM_in_AIG (NCT05238181)
- Testing
- Assess pyloric or pseudopyloric metaplasia of corpus by H&E stains, Assess pyloric or pseudopyloric metaplasia of corpus by TFF2 immunohistochemistry stains, The assessment of corpus-predominant gastritis index (CGI), Operative Link for Gastritis Assessment (OLGA), and Operative Link on Gastric Intestinal Metaplasia assessment (OLGIM)
- Where
- Taiwan
- Volunteers
- 300 people
- Sponsor
- National Cheng-Kung University Hospital
Helicobacter Pylori Infection
Efficacies of Bismuth-amoxicillin-vonoprazan Triple Therapy and Bismuth Quadruple Therapy
(1) To compare the efficacy and safety of a 14-day bismuth-amoxicillin-vonoprazan triple therapy versus a 14-day bismuth-based quadruple therapy as first-line treatments for H.
- Trial name
- NCT07358130
- Testing
- vonoprazan, tripotassium dicitrate bismuthate, amoxicilline, rabeprazole, tripotassium dicitrate bismuthate, tetracycline, metronidazole
- Where
- Taiwan
- Volunteers
- 552 people
- Sponsor
- Kaohsiung Medical University
Helicobacter Pylori Eradication
Serum Pepsinogen After H. Pylori Eradication
Helicobacter pylori has been recognized as a major pathogen in gastric carcinogenesis. Current guidelines recommend the H. pylori "test-and-treat" strategy for the purpose of primary and secondary gastric cancer prevention.
- Trial name
- NCT03924375
- Where
- South Korea
- Volunteers
- 100 people
- Sponsor
- Soonchunhyang University Hospital
Helicobacter Pylori Infection, Early Gastric Cancer
Effects of H. Pylori Eradication on the Gastric Preneoplastic Lesion and Neoplasm After ESD
This study evaluates whether Helicobacter pylori eradication improves precancerous lesions including glandular atrophy and intestinal metaplasia as well as metachronous cancers or dysplasias after endoscopic mucosal resection for…
- Conditions
- Helicobacter Pylori Infection, Early Gastric Cancer, Endoscopic Resection
- Trial name
- NCT02407119
- Testing
- 7 day H.pylori eradication Omeprazole or Rabeprazole, Clarithromycin, Amoxicillin
- Where
- South Korea
- Volunteers
- 470 people
- Sponsor
- National Cancer Center, Korea
Helicobacter Pylori Infection
Food Effect on the Eradication Rate of H. Pylori With Triple Therapy With Esomeprazole
The purpose of the study is assess whether the various forms of triple regimen of administration of treatment of Helicobacter pylori (before meals (fasting), after meals, and any independent mealtime) influence the rate of…
- Trial name
- NCT02552641
- Testing
- Food effect, Esomeprazole, Amoxicillin
- Where
- Brazil
- Sponsor
- EMS
Helicobacter Pylori Infection
Efficacy of High-dose Dual Therapy vs Bismuth-containing Quadruple Therapy for Rescue Treatment of Hp Infection
Up to now, there is few randomized, large scale study prospectively and simultaneously comparing the efficacy, adverse effects and patient adherence of high-dose dual therapy (HDDT) and bismuth-containing quadruple therapy (BQT)…
- Trial name
- NCT02490839
- Testing
- High-dose dual therapy (rabeprazole, amoxicillin), Bismuth-containing quadruple therapy (rabeprazole, tripotassium dicitrate bismuthate, metronidazole, tetracycline)
- Where
- Taiwan
- Volunteers
- 450 people
- Sponsor
- National Taiwan University Hospital
Rescue Therapy for Helicobacter Pylori
Quadruple Therapy Versus Dual Therapy as Rescue Regimens for Helicobacter Pylori Infection
The eradication rates of first-line treatment for Helicobacter pylori(Hp) infection are not satisfactory. The study aims to compare the efficacy and safety between quadruple therapy with furazolidone and dual therapy with high…
- Trial name
- NCT01805934
- Testing
- RBLF, RA
- Where
- China
- Volunteers
- 114 people, healthy volunteers welcome
- Sponsor
- Shanghai Jiao Tong University School of Medicine
H. Pylori Infection
A Randomized, Open-label Study on Helicobacter Pylori Eradication With Standard Triple Regimen Plus Acetazolamide
Helicobacter pylori infection is associated with several gastric diseases, including gastritis, peptic and duodenal ulcers, gastric carcinoma and MALToma. In 1994, the WHO classified the organism as a type 1 carcinogen.
- Trial name
- NCT02090738
- Testing
- Acetazolamide group, Standard regimen group
- Where
- South Korea
- Sponsor
- Yonsei University
Helicobacter Pylori Infection, Family History of Stomach Cancer
Comparison of 7-day PPI-based Standard Triple Therapy and 10-day Bismuth Quadruple Therapy for H. Pylori Eradication
In this randomized controlled trial, we investigate the effect of 10-day bismuth quadruple therapy in comparison with that of 7-day PPI-based standard triple as 1st line treatment for H. pylori.
- Trial name
- NCT02557932
- Testing
- Standard triple therapy, Bismuth quadruple therapy
- Where
- South Korea
- Volunteers
- 352 people, healthy volunteers welcome
- Sponsor
- National Cancer Center, Korea
Myocardial Infarction, Helicobacter Pylori Infection
HELicobacter Pylori Screening to Prevent Gastrointestinal Bleeding in Patients With Acute Myocardial Infarction
Background: Potent antithrombotic therapy has improved prognosis for patients with acute myocardial infarction (MI) significantly, however, at a price of increased bleeding risk. Helicobacter pylori (H.
- Conditions
- Myocardial Infarction, Helicobacter Pylori Infection, GastroIntestinal Bleeding, Cardiovascular Diseases
- Trial name
- HELP-MI (NCT05024864)
- Testing
- Urea breath test (UBT)
- Where
- 35 sites in Sweden
- Volunteers
- 20,000 people
- Sponsor
- Karolinska Institutet
Helicobacter Pylori Infection
Qingre Huashi Granules Combined the Modified Dual Therapy for Helicobacter Pylori Infection
This is an open-label, randomized controlled trial. The aim of the study is to evaluate the efficacy and safety of the Qingre Huashi Granules combined the modified dual therapy (or called high dose dual therapy) for Helicobacter…
- Trial name
- NCT05364619
- Testing
- Qingre Huashi Granules combined the modified dual therapy, Bismuth containing quadruple therapy
- Where
- 3 sites in China
- Volunteers
- 160 people
- Sponsor
- Peking University First Hospital
Helicobacter Pylori Infection
Clarithromycin Triple Therapy Plus Bismuth for Helicobacter Pylori First-line Treatment
Standard triple therapy including a proton pump inhibitor (PPI) and clarithromycin with either amoxicillin or metronidazole are no longer recommended as empirical first-line therapy to treat Helicobacter pylori infection because…
- Trial name
- NCT02732249
- Testing
- Esomeprazole, Bismuth Potassium Citrate, Clarithromycin
- Where
- China
- Volunteers
- 66 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Helicobacter Pylori Infection, Tegoprazan
Efficacy and Safety of Tegoprazan Dual Therapy and Furazolidone-based Bismuth Quadruple Therapy for Helicobacter Pylori Eradication: A Prospective, Multicenter, Open-label, Randomized Controlled Clinical Study
To compare the efficacy and safety of Tegoprazan-amoxicillin dual therapy and bismuth quadruple therapy based on furazolidone in the treatment of Helicobacter pylori eradication, the eradication rate, patient compliance, and…
- Conditions
- Helicobacter Pylori Infection, Tegoprazan, Furazolidone
- Trial name
- NCT06340334
- Testing
- Tegoprazan-amoxicillin dual therapy
- Where
- China
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Nanjing First Hospital, Nanjing Medical University
H.Pylori Infection
Intrafamilial Helicobacter Pylori Infection in Hong Kong
It is a single-centre, prospective cohort study, which will be conducted in a tertiary academic hospital. The study aims to investigate intrafamilial H. pylori infection status and to identify risk factors for H.
- Trial name
- NCT06425393
- Testing
- Urea beath test (UBT)
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Chinese University of Hong Kong
Helicobacter Pylori, Gut Microbiota
Helicobacter Pylori Eradication Therapy in Portugal
Helicobacter pylori (H. pylori) infection remains a major public health problem, with an estimated prevalence of over 50% worldwide and 60-86% for Portugal. H.
- Conditions
- Helicobacter Pylori, Gut Microbiota, Immunology
- Trial name
- NCT05449028
- Testing
- H. pylori eradication scheme A, H. pylori eradication scheme B, H. pylori eradication scheme C
- Where
- Portugal
- Volunteers
- 230 people
- Sponsor
- Unidade Local de Saúde de Coimbra, EPE
Helicobacter Pylori Infection
Concomitant, Sequential, and Standard Triple Therapy for H. Pylori Infection
To simultaneously compare the efficacies of 7-day triple, 10-day sequential and 7-day quadruple therapies for H. pylori infection in Taiwan. Consecutive H.
- Trial name
- NCT01769365
- Testing
- 7-day quadruple therapy, 10-day sequential therapy, 7-day standard triple therapy
- Where
- Taiwan
- Volunteers
- 307 people
- Sponsor
- Kaohsiung Veterans General Hospital.
Helicobacter Pylori Infection
Rifabutin-containing Triple Therapy for Treatment of Helicobacter Pylori
Rifabutin has good chemical stability and low drug resistance rate in acidic gastric environment. Therefore, it is often used in combination with amoxicillin proton pump inhibitor for the rescue treatment of Helicobacter pylori.
- Trial name
- NCT04879992
- Testing
- Esomeprazole, Bismuth Potassium Citrate, Tetracycline,Metronidazole
- Where
- China
- Volunteers
- 413 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Helicobacter Pylori Infection, Atrophic Gastritis
Artificial Intelligence for Determination of Gastroscopy Surveillance Intervals
The purpose of this study is to develop and validate a clinical decision support system based on automated algorithms. This system can use natural language processing to extract data from patients' endoscopic reports and…
- Conditions
- Helicobacter Pylori Infection, Atrophic Gastritis, Intestinal Metaplasia, Low Grade Intraepithelial Neoplasia
- Trial name
- NCT05631015
- Testing
- AI recongnize disease and generate recommendations
- Where
- China
- Volunteers
- 2,000 people
- Sponsor
- Xiuli Zuo
Eradication Rates of the Two Regimens
Clarithromycin-based Triple Therapy for 14 Days Versus Sequential Therapy 10 Days in the First Line Therapy
The investigators aimed to compare the eradication rates of sequential therapy for 10 days versus triple therapy for 14 days
- Trial name
- THC (NCT01607918)
- Testing
- D1-D5: (lansoprazole + amoxicillin ) D6-D10: (lansoprazole+clarithromycin +metronidazole), D1-D14: (lansoprazole + clarithromycin + amoxicillin)
- Where
- Taiwan
- Volunteers
- 1,300 people
- Sponsor
- National Taiwan University Hospital
Helicobacter Infections, Bacterial Infections
Study of the Safety and Effectiveness of Rabeprazole in Treatment of Helicobacter Pylori Infection in Adults.
The purpose of the study is to confirm the safety and effectiveness of rabeprazole in the treatment of adult patients with Helicobacter pylori (H. pylori) infection in routine clinical practice.
- Trial name
- NCT00216450
- Testing
- rabeprazole sodium
- Volunteers
- 80 people
- Sponsor
- Janssen Cilag Pharmaceutica S.A.C.I., Greece